Febuxostat, a non-purine selective inhibitor of xanthine oxidase is used to treat chronic hyperuricemia in gout patients.
Teijin Pharma signed a licensing agreement with SK Chemicals in July 2004 for the development and marketing of Febuxostat in Korea, and as a licensee, SK Chemicals is marketing the Febuxostat under the brand name Feburic.
Takeda Pharmaceuticals North America and Takeda Canada who are also licensee have rights to market Febuxostat under the brand name Uloric.
Menarini Group will market the drug under the brand name Adenuric in Europe including France, the U.K., Germany, Ireland, Italy, Greece, Austria, Spain and Cyprus.